PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7386472

Cumulative sum control charts for admixture quality control.

R L Sanford
View original source ↗Export metadata ↓

Abstract

The use of cumulative sum control charts as a means of monitoring the sterility of i.v. admixtures produced by a centralized service is discussed. To create a sum control chart, acceptable and rejectable quality levels must be determined. Frequency of sampling will responsiveness and can be varied to affect the length of time necessary to detect an unacceptable shift in product quality. Cumulative sum control charts allow monitoring to be carried out on a cost versus benefit basis, and can be used to provide a basis for action on production of existing product and to maintain or improve product quality in the future.

Explore related subjects

Drug CombinationsDrug CompoundingDrug ContaminationInfusions, ParenteralQuality ControlStatistics as TopicJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R L Sanford. 1980. Cumulative sum control charts for admixture quality control.. https://pubmed.ncbi.nlm.nih.gov/7386472/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Multi-target therapeutics: when the whole is greater than the sum of the parts.

Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders. Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas. The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms. In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.

Drug Combinations↗
PubMed2006

A nanoscale study of particle friction in a pharmaceutical system.

Studies of single particle interactions in dry powder inhaler (DPI) formulations using atomic force microscopy (AFM) have recently grown in popularity. Currently, these experiments are all based on measuring particle adhesion forces. We broaden this approach by presenting a novel AFM friction study of single particles in a pharmaceutical system, to examine forces acting parallel to a surface. The sliding friction signal of lactose particles attached to AFM cantilevers was recorded in lateral force (LF) mode over 5 microm x 5 microm areas on five different surfaces chosen to represent both relevant inter-particle and particle-surface interactions. A ranking of friction forces was obtained as follows: glass approximately equal to zanamivir >zanamivir-magnesium stearate (99.5%/0.5%, w/w) blend approximately equal to magnesium stearate approximately equal to PTFE. The addition of magnesium stearate to the zanamivir surface dominated and significantly reduced the friction (Kruskal-Wallis test, P<0.001). AFM images of the contacting asperities of the lactose particles show changes in contact morphology due to two processes. Firstly the asperity wears flat due to abrasion and secondly small magnesium stearate particles transfer onto the asperity. It is proposed that in combination with AFM particle adhesion measurements, this method could be used to screen new formulations and the effectiveness of tertiary components in modifying carrier-drug interactions.

Drug Combinations↗